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LETTER TO THE EDITOR
Oral contraceptives and breast cancer
Sir- The Committee on Safety of Medicines is grateful for
having been able to review, prior to publication, the recent
paper by McPherson et al. (1987).
This paper adds to the considerable body of knowledge
which has now accumulated on this subject. At least eight
substantial case-control studies in which the possible
relationship between oral contraceptive use and breast cancer
was investigated have been published since 1980. Most of
these studies, including the largest of them - the American
Cancer and Steroid Hormone (CASH) study- have provided
no cause for concern. Some, however, have raised questions
about a possible adverse effect of prolonged oral
contraceptive use in early life.
The publication by McPherson and colleagues has
suggested that there may be a two and a half fold increase in
the risk of breast cancer in women up to 45 years of age
who have had four or more years of oral contraceptive use
before their first full term pregnancy. The authors point out
that their data do not directly reflect upon the use of the
modern low dose oral contraceptive pills. In addition, this
study has found no association between oral contraceptive
use after first full term pregnancy and breast cancer either in
women under 45 years of age or in older women. The paper
by McPherson and colleagues (1987) extends their previously
reported results (McPherson et al., 1983) which were fully
considered by the CSM at the time of their appearance.
The CSM has considered the additional results now being
made available in the light of all the current evidence. The
Committee will continue to monitor the several studies which
are still in progress on this subject but agrees with the view
of McPherson et al. that the newly reported findings do not
indicate the need to change at this time the current advice
regarding the use of the presently available oral
contraceptive agents. Thus, the Committee remains of the
view that women receiving oral contraceptives should be
prescribed a product with the lowest suitable content of both
oestrogen and progestogen.
Yours etc.,
A.W. Asscher,
Chairman, Committee on Safety of Medicines,
Market Towers,
1 Nine Elms Lane,
London SW8 5NQ
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